SenesTech Inc (NASDAQ:SNES) has received an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12 month consensus price target of $14.50 for the company and are anticipating that the company will post ($0.27) earnings per share for the current quarter, according to Zacks. Zacks has also assigned SenesTech an industry rank of 176 out of 265 based on the ratings given to related companies.
Several brokerages have issued reports on SNES. Zacks Investment Research raised shares of SenesTech from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. Craig Hallum set a $3.00 target price on shares of SenesTech and gave the company a “buy” rating in a report on Wednesday, November 22nd.
Shares of SenesTech (NASDAQ:SNES) traded up $0.01 during trading on Friday, reaching $0.78. 82,100 shares of the company’s stock traded hands, compared to its average volume of 158,163. SenesTech has a 52 week low of $0.75 and a 52 week high of $10.69. The company has a current ratio of 2.94, a quick ratio of 2.67 and a debt-to-equity ratio of 0.17.
SenesTech (NASDAQ:SNES) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.03. SenesTech had a negative net margin of 14,473.40% and a negative return on equity of 190.41%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.25 million. research analysts forecast that SenesTech will post -1.26 EPS for the current year.
Several large investors have recently modified their holdings of the company. Gilder Gagnon Howe & Co. LLC boosted its holdings in shares of SenesTech by 3.0% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 1,078,499 shares of the company’s stock valued at $1,995,000 after acquiring an additional 31,330 shares in the last quarter. Prudential PLC boosted its holdings in SenesTech by 49.3% during the second quarter. Prudential PLC now owns 447,971 shares of the company’s stock worth $2,661,000 after buying an additional 147,971 shares in the last quarter. TCI Wealth Advisors Inc. purchased a new stake in SenesTech during the third quarter worth about $748,000. Skylands Capital LLC boosted its holdings in SenesTech by 139.8% during the third quarter. Skylands Capital LLC now owns 87,483 shares of the company’s stock worth $162,000 after buying an additional 51,000 shares in the last quarter. Finally, White Pine Capital LLC purchased a new stake in SenesTech during the second quarter worth about $110,000. 14.44% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://ledgergazette.com/2017/12/06/zacks-senestech-inc-snes-receives-average-rating-of-strong-buy-from-analysts.html.
SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.